Our groups interests concern clinical research, focussing on clinical investigation involving varied topics with the common theme of immediate relevance to patients with diabetes. These include aspects of the pathophysiology of hypoglycaemia in diabetes, the contribution of hypoglycaemia to the increased risk of sudden death in young people with Type 1 diabetes (the 'dead in bed' syndrome), the clinical benefits of insulin analogues and trials of complex interventions to enable more effective self-management in people with diabetes. Other research has also explored the potential of technology to improve blood glucose control and reduce hypoglycaemia in diabetes and work with the pharmaceutical industry in evaluating the benefit of new insulins (Heller et al Diabetes Care 1999, Heller et al Lancet 2012) and participated in multi-centre trials evaluating technology (Little et al Diabetes Care 2014) and closed loop devices (Thabit et al Lancet Diabetes Endocrinol 2014). Designed and subsequently led the recently completed REPOSE Trial, a multi-centre.£2m HTA funded RCT conducted in England and Scotland, measuring the effectiveness of insulin pump therapy in adults with type 1 diabetes."